Q-omics provides the consensus-scored TEX264 profile across patient tissues and cancer cell-line models. TEX264 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TEX264 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TEX264 RNA expression shows 18,020 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where TEX264 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX264 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX264 survival associations across molecular data types. TEX264 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX264 RNA expression–survival associations across cancer types. High TEX264 expression shows unfavorable associations in LGG, SKCM and MESO, but favorable associations in KIRP, STAD and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TEX264 RNA expression.
This table summarizes TEX264 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TEX264. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX264 shows lower tumor expression in KIRC, LUSC and THCA and higher tumor expression in LIHC, COAD and BRCA. The KIRC box plot shows higher TEX264 RNA expression in normal versus tumor tissue (log2 FC = −0.689, t-test p < 0.001).
This table shows molecular features associated with TEX264 in patient tissues and cancer cell lines. In patient samples, TEX264 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX264 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
